Advaxis Inc. (NASDAQ:ADXS)’s share price was down 3.5% on Wednesday . The stock traded as low as $11.17 and last traded at $11.38, with a volume of 582,398 shares. The stock had previously closed at $11.79.

Several equities analysts recently weighed in on ADXS shares. Jefferies Group reissued a “buy” rating on shares of Advaxis in a research report on Thursday, August 25th. FBR & Co reissued an “outperform” rating and set a $34.00 price objective on shares of Advaxis in a research report on Tuesday, May 17th. HC Wainwright reissued a “buy” rating and set a $23.00 price objective on shares of Advaxis in a research report on Friday, August 5th. Finally, Barclays PLC boosted their price objective on Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 3rd. Six investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $25.80.

The stock’s market capitalization is $396.01 million. The company’s 50-day moving average is $11.30 and its 200-day moving average is $9.04.

In other news, Director David Sidransky sold 22,808 shares of the firm’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $15.01, for a total transaction of $342,348.08. Following the sale, the director now owns 91,759 shares in the company, valued at approximately $1,377,302.59. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Richard J. Berman sold 18,000 shares of the firm’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $15.21, for a total transaction of $273,780.00. Following the sale, the director now owns 66,430 shares in the company, valued at approximately $1,010,400.30. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.